bioAffinity Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

bioAffinity Technologies şirketinin toplam hissedar öz sermayesi $3.1M ve toplam borcu $288.8K olup, bu da borç-öz sermaye oranını 9.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $6.6M ve $3.4M dir.

Anahtar bilgiler

9.3%

Borç/özkaynak oranı

US$288.76k

Borç

Faiz karşılama oranı	n/a
Nakit	US$756.58k
Eşitlik	US$3.12m
Toplam yükümlülükler	US$3.43m
Toplam varlıklar	US$6.55m

Son finansal sağlık güncellemeleri

Here's Why bioAffinity Technologies (NASDAQ:BIAF) Must Use Its Cash Wisely

Mar 05

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BIAF 'nin kısa vadeli varlıkları ( $2.5M ) kısa vadeli yükümlülüklerini ( $2.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: BIAF şirketinin kısa vadeli varlıkları ( $2.5M ) uzun vadeli yükümlülüklerini ( $939.8K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BIAF şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: BIAF şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BIAF son raporlanan serbest nakit akışına göre 1 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: BIAF serbest nakit akışı tahminlerine göre 1 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

bioAffinity Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why bioAffinity Technologies (NASDAQ:BIAF) Must Use Its Cash Wisely

Recent updates

New major risk - Shareholder dilution

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

bioAffinity Technologies, Inc. Announces Executive Changes

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.662782 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $2.662782 million.

bioAffinity Technologies, Inc. Appoints J. Michael Edwards as Chief Financial Officer

New major risk - Share price stability

bioAffinity Technologies, Inc. Announces Chief Financial Officer Changes

bioAffinity Technologies, Inc. Announces Chief Financial Officer Changes

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

bioAffinity Technologies, Inc. announced that it has received $1.302084 million in funding

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.45 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $0.45 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $0.45 million.

New major risk - Share price stability

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.18 loss in 1Q 2023)

bioAffinity Technologies, Inc., Annual General Meeting, Jun 04, 2024

Full year 2023 earnings released: US$0.91 loss per share (vs US$1.81 loss in FY 2022)

bioAffinity Technologies, Inc. announced that it has received $2.624 million in funding

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million.

New major risk - Share price stability

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $2.5 million.

bioAffinity Technologies, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Here's Why bioAffinity Technologies (NASDAQ:BIAF) Must Use Its Cash Wisely

bioAffinity Technologies, Inc. Appoints Sandeep Bansal to Medical and Scientific Advisory Board

bioAffinity Technologies, Inc. Appoints Jamie Platt, Ph.D., to its Board of Directors

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$1.17 loss in 3Q 2022)

bioAffinity Technologies, Inc. Provides Earnings Guidance for the Year 2023 and for the Next 12 Months(fourth quarter 2023 to third quarter 2024)

bioAffinity Technologies, Inc. Appoints Dallas J. Coleman as National Director of Sales

New major risk - Share price stability

bioAffinity Technologies, Inc. Announces Board Changes

New major risk - Financial position

AMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer

bioAffinity Technologies, Inc. Appoints Julie Anne Overton as Director of Corporate Communications

bioAffinity Technologies, Inc. Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

Bioaffinity Technologies Announces Notice to Award U.S. Patent and Trademark Office Protecting Novel Compounds for Specific Delivery of Cancer Treatments

Bioaffinity Technologies Announces Joining of Sheila Habib and David Hill to Scientific and Medical Advisory Board

bioAffinity Technologies, Inc. Announces the People’S Republic of China Awarded Certificate of Patent to Company’S Wholly Owned Subsidiary Oncoselect® for Patent “Porphyrin Compounds and Compositions Useful for Treating Cancer”

bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference

bioAffinity Technologies receives ~$7.7M from exercise of warrants

BioAffinity stock jumps 42% after peer-reviewed data on lung test

bioAffinity Technologies, Inc. has completed an IPO in the amount of $8.033281 million.

bioAffinity Technologies, Inc. has completed an IPO in the amount of $8.033281 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin